Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients

ConclusionsTotal direct cost and LOS for VTE admission and total cost in 1-year post-discharge period were significantly lower in patients initiated and discharged with rivaroxaban than those of warfarin.

Source: Cardiovascular Drugs and Therapy - March 18, 2019 Category: Cardiology Source Type: research